Christophe Weber, Takeda CEO (Kosuke Okahara/Bloomberg via Getty Images)
Takeda defends Alzheimer's pact, TYK2 potential as restructuring is in 'full swing'
In its quarterly update on Wednesday, Takeda executives said the Japan-based pharma giant’s $900 million restructuring is in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
